Company Record · Rare Disease and Generics · Nasdaq: ANIP

ANI Pharmaceuticals: 970 Employees, None in ASEAN

ANI Pharmaceuticals is a Princeton, New Jersey company that turned a Minnesota generics plant into a rare disease business with 883.4 million US dollars of 2025 revenue and guidance of up to 1.13 billion for 2026. It employs 970 people across seven countries, runs three manufacturing sites, and holds no facility anywhere in Southeast Asia. This record sets out what the company is, where its plants sit, and what a Philippine site, a Philippine product registration, and a Philippine site visit would each involve.

Independent research published by RB Advertising. We are not affiliated with ANI Pharmaceuticals, Inc., we hold no position in the company, and nothing here states or implies a commercial relationship with it.

883.4M Net revenue, 2025, in US dollars
+24.8% Nine month revenue growth, 2026
138.7M Cortrophin Gel revenue, third quarter 2026
16 New generics launched, year to date 2026
0 Manufacturing sites in ASEAN
01 Section of 10

Four Times the Revenue in Four Years, Built by Buying and Filing

ANI has grown from 216.1 million US dollars of revenue in 2021 to 883.4 million in 2025, and it has done that with three moves that matter to a country pitching itself as a manufacturing base: it bought a plant, it bought a product line, and it filed its own applications rather than only distributing other companies products.

FY 2021 216.1M
FY 2022 316.4M
FY 2023 486.8M
FY 2024 614.4M
FY 2025 883.4M
9M 2026 794.3M
Net revenue in US dollars. The 2026 bar is nine months to 30 September, not a full year, and is marked with the hatched fill for that reason. Source: Form 10-K XBRL for 2021 to 2025, Form 10-Q for the third quarter of 2026.

Where the third quarter of 2026 came from

Cortrophin Gel 47.7% Generics 35.9% ILUVIEN 7.7% Brand royalties 4.0% Brands 3.4% Other revenue 1.3%
Rare disease

Cortrophin Gel Carries the Company

The purified corticotropin product produced 138.7 million US dollars in the third quarter of 2026, up 36.1 percent, and management guides to 480 to 500 million for the full year. Growth is coming from a gout expansion plus nephrology, neurology, rheumatology, ophthalmology, and pulmonology. It is a specialty pharmacy product with a cold chain, which is exactly the kind of line that needs regional distribution infrastructure rather than a single warehouse.

Generics

Sixteen Launches in Nine Months

Generics contributed 104.5 million US dollars in the third quarter, up 10.7 percent, and the company launched 16 new generic products in the first nine months of 2026. This is the segment that competes on cost of goods, and cost of goods is the argument for a second manufacturing geography.

Capital allocation

Buy the Asset, Then Build the Volume

Novitium Pharma in 2021 brought development and manufacturing capacity. Alimera Sciences in 2024 brought ILUVIEN and an international commercial footprint. In November 2026 the company made a recommended cash offer for Egetis Therapeutics, adding EMCITATE for MCT8 deficiency at about 560 million US dollars. The pattern is consistent: buy a validated asset, then scale it. A Philippine contract manufacturing partnership fits that pattern before it fits a greenfield build.

02 Section of 10

Three Plants, Seven Countries, One Empty Region

The physical footprint is small and concentrated. Two plants sit in Baudette, Minnesota, a town of roughly a thousand people on the Rainy River, and one sits in East Windsor, New Jersey. Everything the company makes in the United States leaves from those three buildings.

01

Baudette, Minnesota

Owned · Two plants

The original site, and still the centre of gravity for United States manufacturing. The campus carries two of the three plants in the group and sits on the same river town where the company has operated since the 1990s.

02

East Windsor, New Jersey

Owned · One plant

The New Jersey corridor that Novitium Pharma brought into the group in 2021, together with a development team and a pipeline of filings. It sits close to the Princeton head office, which is how a company ends up running operations and regulatory affairs from the same state.

03

Everywhere Else

Offices only · No plant

India holds 148 staff, the largest footprint outside the United States, and the United Kingdom, Germany, Portugal, and Ireland hold the European commercial and distribution functions. None of these is a manufacturing site, and none of them is in ASEAN.

What the three plants can make
CapabilityWhat it coversWhat a Philippine site would need to match it
Oral solid doseTablets and capsules, including film, sugar, and enteric coatings, and modified release forms.Rotary compression, fluid bed drying, coating, and a qualified stability program.
Semi solidsCreams, ointments, and gels mixed and filled in sanitary vessels.Jacketed mixing, clean in place loops, and a topical filling line.
LiquidsOral solutions and suspensions for adult and pediatric use.Purified water generation, stainless steel compounding, and bottle filling.
TopicalsDermatological and ophthalmic adjacent dose forms outside sterile presentation.Dedicated suites, particle control, and compatible primary packaging supply.
Controlled substancesSchedule products manufactured under separate handling and security controls.Vaults, camera coverage, and a second licence on top of the standard plant permit.
Potent compoundsProducts requiring fully contained manufacturing and pressure cascades.Containment suites, dedicated air handling, and occupational exposure limits.

Where the 970 people are

Headcount as reported at January 2026 in the Form 10-K. The dashed track is not a projection or a target. It records what the filing records: no Philippine employees and no Southeast Asian site.

03 Section of 10

Six Hundred Eighty Million Neighbours, No Local Floor

ANI sells into the United States, Europe, and Canada. It develops in India. It manufactures in Minnesota and New Jersey. The one large regulated market it has never established a base in is ASEAN, a bloc of ten countries and roughly 680 million people where medicaments move between member states at zero tariff under the ASEAN Trade in Goods Agreement.

The arithmetic of a second site

A generics business with 16 launches in nine months competes on cost of goods and on speed to file. Both are procurement and people problems before they are science problems. A Philippine plant does not replace Baudette, and it is not meant to. It gives the generics line a cost base outside the dollar, a filing route into ASEAN, and a supply point that sits inside the same tariff bloc as its customers.

Why the market is not speculative

The Philippine pharmaceutical market is already over 5 billion US dollars, and the Universal Health Care Act has been pushing reimbursement volume toward generics. Republic Act 11981, the Tatak Pinoy Act, directs public hospitals and state agencies to give procurement preference to domestic producers. A locally manufactured product is not only cheaper to ship. On the public tender side it is preferred by statute.

680M Consumers in ASEAN, reachable at zero tariff on medicaments under ATIGA
5B+ US dollars of Philippine pharmaceutical demand, growing under universal health care
16 Generic products launched in nine months, each one a candidate for regional filing
0 Southeast Asian sites today, the gap this page exists to describe

The honest counterweight. A Philippine plant is not free money. Product registration has to be earned dossier by dossier, the public payer sets reference prices, and the local generics industry is already competitive on simple oral solids. The case for the Philippines is not a margin arbitrage on day one. It is a ten year position inside a bloc that is closing its supply gaps, entered at a cost base that a Minnesota plant cannot match.

04 Section of 10

Four Statutes Decide Whether the Numbers Work

The Philippine incentive architecture is not a brochure promise. It is four laws and one executive order, each with a defined benefit and a defined condition. Read them before a site shortlist, not after.

01

CREATE MORE Sets the Tax Rate

Republic Act 12066 cuts the corporate income tax for a registered enterprise to 20 percent. It grants an income tax holiday of up to seven years, then ten years at the 5 percent special corporate income tax on gross income earned, or the enhanced deductions regime instead. Local purchases are VAT zero rated and imported capital equipment enters duty free, which matters when a cleanroom and a tableting suite are the capital budget.

20 percent corporate income tax
02

The Foreign Investments Act Allows Full Ownership

Republic Act 11647 amended the Foreign Investments Act and moved pharmaceutical manufacturing off the negative list. A foreign company can hold 100 percent of a Philippine manufacturing subsidiary without a Filipino partner. The constitutional limit is on land ownership, not on the plant, the licence, or the intellectual property.

100 percent foreign equity
03

The Investors Lease Act Gives 75 Years

Republic Act 7652 lets a foreign investor lease private industrial land for 50 years with a 25 year renewal, so the tenure outlasts the depreciation schedule of the plant. Inside a PEZA economic zone the alternative is a ready built standard factory, which removes the construction phase and the land question in one step.

75 year land tenure
04

Green Lane Removes the Queue

Executive Order 18 created a One Stop Action Center for Strategic Investments under the Board of Investments and the Anti Red Tape Authority. A designated project gets priority processing across national agencies and local governments. For a pharmaceutical build, the value is concentrated in the permits that sit between a signed lease and a validated cleanroom.

Priority permit processing
Statutory references a site team will be asked for
InstrumentWhat it does for a pharmaceutical investorWhere the detail sits
RA 12066Corporate rate, income tax holiday, special rate, VAT zero rating, duty free capital equipment.PEZA and CREATE MORE against Vietnam incentives
RA 11647Foreign equity ceiling removed for pharmaceutical manufacturing.Foreign Investments Act reference
RA 7652Lease tenure of 50 years plus a 25 year renewal for industrial land.Investors Lease Act reference
RA 11981Procurement preference for domestic producers in public health facilities.Stated in the section above
EO 18Green Lane designation and priority processing for strategic investments.Invest in the Philippines overview
05 Section of 10

The Dose Forms Already Match the Zones

Nothing in the ANI capability list is exotic by Philippine standards. Oral solids, semi solids, liquids, and topicals are exactly what the Bulacan and Laguna contract manufacturing base already produces for the domestic market and for export. The two hard cases are containment and controlled substances, and both are scheduled rather than solved.

Capability, cluster, and the condition attached
CapabilityPhilippine clusterCondition attached
Oral solid doseFirst Bulacan Industrial City, Laguna Technopark, First Philippine Industrial Park in Batangas.The deepest local bench. Toll manufacturers here already run high speed compression and blister lines, so a first product transfer is a scheduling problem.
Semi solids and topicalsBulacan, close to the port and to the Metro Manila contract packing base.Requires a dedicated topical suite rather than shared tablet space, which changes the floor plan but not the utilities.
Oral liquidsBulacan and Laguna.Purified water capacity is the binding constraint. Size the generation loop for the highest volume SKU, not the average.
Potent compoundsAny PEZA zone with containment capable HVAC, usually a purpose built unit inside an existing park.Pressure cascades, occupational exposure limits, and a higher validation workload. Plan a separate building, not a room.
Controlled substancesPEZA zone with secured storage and a separate regulatory track.Requires Dangerous Drugs Board and PDEA authorisation on top of the plant licence. Sequence this after the first products are registered, never before.
Cold chainMetro Manila specialty distributors with refrigerated storage and validated last mile delivery.Where a Cortrophin style product would start. Distribution first, manufacturing later, and only after the payer pathway is clear.

Cluster detail is drawn from the packaged medicaments manufacturing profile, which carries the zone, utility, and cleanroom specifics for each site.

06 Section of 10

Register First, Borrow a Line Second, Build Third

The failure mode in pharmaceutical market entry is signing a build before the dossier exists. The sequence below puts regulatory proof ahead of capital, so each stage is funded by a stage that already worked.

1 Stage one

Register and Import

Incorporate a Philippine subsidiary, obtain a Licence to Operate as an importer and distributor, and file the first dossiers with the Food and Drug Administration of the Philippines in ASEAN Common Technical Dossier format. Each product needs its own Certificate of Product Registration. This stage produces revenue, not capacity, and it is the only stage that tells you whether the payer will actually cover the product.

Capital: low Output: first certificates of registration Risk: dossier rejection, cured by resubmission
2 Stage two

Borrow a Registered Line

Transfer one or two oral solid products to a PEZA registered toll manufacturer in Bulacan or Laguna. That means technology transfer, exhibit batches, analytical method validation, and stability studies under the local climate zone. It produces exportable product without a construction project, and it stress tests whether the local supply chain can hold your specification.

Capital: moderate Output: locally manufactured batches Risk: transfer delays, cured by running two candidates
3 Stage three

Build Inside an Ecozone

Only after stages one and two work: a lease of 75 years or a ready built PEZA factory, ISO 14644 classified cleanrooms, design, installation, operational, and performance qualification for the HVAC and water systems, a manufacturer Licence to Operate, and then export under ATIGA rules of origin. Green Lane designation compresses the permit sequence but not the validation sequence.

Capital: high Output: owned capacity and ASEAN export Risk: fixed cost before volume, cured by stage two demand data
07 Section of 10

The Plant, the Regulator, and the Beach in One Trip

Luzon puts the industrial belt, the regulator, and the airport inside one day of driving. That is the practical reason a due diligence trip to the Philippines ends up being worth more than the meetings on the calendar.

30 Days, No Visa

A United States passport holder enters visa free for 30 days, extendable at the Bureau of Immigration. Carry a return or onward ticket.

eTravel Within 72 Hours

Register on the eTravel portal inside the 72 hours before arrival. The confirmation is checked at the airport, not at the hotel.

Six Months of Passport

The passport must be valid for at least six months beyond the intended stay. Renew before booking, not after.

Day one to two

Manila and Intramuros

Land at Ninoy Aquino, meet the Food and Drug Administration and the Board of Investments in the same week, and walk the walled city at dusk. The business districts where a partner office would sit are twenty minutes from the old town.

Day three

Laguna or Batangas

Two hours by road from Metro Manila, outside peak traffic. A plant walk, a utility tour, and a meeting with the ecozone administrator fit into a single day, and the drive back clears before the evening news.

Day four

Anilao and the Batangas Coast

The dive coast begins where the industrial belt ends. An extra night here turns a factory inspection into a long weekend without a second flight.

Day five to seven

Cebu and Bohol

A short domestic flight from Manila to a different island group. Ports, a second industrial corridor, the Chocolate Hills, and a coastline that reads as a holiday rather than a plant visit.

Optional

Palawan

El Nido and Puerto Princesa, with the underground river and the limestone karsts. This is the leg that persuades a spouse or a board member to make the trip next time.

Optional

Banaue and the Cordillera

The rice terraces north of Manila, two thousand years old and still farmed. A cooler counterpoint to the coast, reached by road or a short flight to Baguio country.

The factory day

Manila to Laguna or Batangas, plant walk in the morning, utility and wastewater review before lunch, ecozone administrator in the afternoon, and back to the hotel before the traffic thickens. Two plants in one day is realistic if both sit in the same park.

The island leg

Ninoy Aquino to Cebu is a short domestic hop with several carriers a day. Bohol is a ferry or a second short flight from there. Booking the island leg for the end of the trip is what turns a compliance run into something a family will join.

Arrival figures for 2025: 6,484,060 inbound visitors, including 5,940,975 foreign visitors, 19 new international routes, and 136 cruise calls. Source: Department of Tourism, January 2026. Entry rules: Philippine Department of Foreign Affairs. For a longer stay, see the tourist visa reference and the extension process.

08 Section of 10

Compared With the Four Countries ANI Already Uses

The useful comparison is not the Philippines against a generic emerging market. It is the Philippines against the four jurisdictions the company already operates in, measured on the things a plant decision actually turns on.

Structural comparison, 2026
DimensionPhilippinesIndiaIrelandUnited States
Role in the ANI map todayNone148 staff, development and manufacturing support8 staff, European commercial753 staff, three plants
Statutory corporate income tax20%22%, or 15% for new manufacturing under section 115BAB12.5%21% federal, plus state
Incentive layered on topIncome tax holiday up to 7 years, then 5% special rate or enhanced deductionsSector production linked schemesResearch and development creditFederal and state credits
Foreign equity in pharmaceutical manufacturing100%100% on the automatic routeFullFull
ASEAN market accessZero tariff on medicaments under ATIGA, cumulative origin under RCEPASEAN trade agreement in force since 2010European Union onlyNone
Regulator and dossier formatPIC/S aligned FDA, ASEAN Common Technical DossierCDSCO, domestic formatHPRA, centralised or mutual recognitionFDA, abbreviated new drug application
Working languageEnglishEnglishEnglishEnglish
Offset from Princeton13 hours ahead10.5 hours ahead5 hours aheadSame day

Tax rates are published statutory figures. The Philippine rate is the rate for a registered enterprise under Republic Act 12066 and is not the rate for an unregistered company. Nothing in this table is a projection of ANI tax expense.

09 Section of 10

Questions That Come Up First

The seven questions a board, a site team, or a family member asks before a Philippine trip or a Philippine filing.

Does ANI Pharmaceuticals have a plant in the Philippines?

No. ANI operates three manufacturing sites: two in Baudette, Minnesota, and one in East Windsor, New Jersey. It employs 970 people across the United States, India, the United Kingdom, Germany, Portugal, Ireland, and Canada. It has no plant, no office, and no employee in the Philippines or anywhere else in Southeast Asia.

Why would a United States rare disease and generics company look at the Philippines?

For three reasons that compound. The country sits inside ASEAN, where 680 million consumers buy medicaments at zero tariff under the ASEAN Trade in Goods Agreement. Its Food and Drug Administration follows PIC/S practice, so a dossier is built in a format international partners already recognise. And Republic Act 11981 gives domestic producers procurement preference in public health facilities, which makes local manufacturing a commercial advantage rather than only a cost saving.

Can a foreign company own 100 percent of a Philippine pharmaceutical plant?

Yes. Republic Act 11647 amended the Foreign Investments Act and opened pharmaceutical manufacturing to full foreign equity. The constitutional restriction is on private land ownership, so a plant site is secured through a lease of up to 75 years under Republic Act 7652, or through a ready built factory inside a PEZA economic zone.

What tax position applies under the CREATE MORE Act?

A registered enterprise pays 20 percent corporate income tax. It can take an income tax holiday of up to seven years followed by ten years at the 5 percent special corporate income tax on gross income earned, or use the enhanced deductions regime instead. Local purchases are VAT zero rated and imported capital equipment enters duty free.

How does product registration work with the Philippine FDA?

Two steps, in order. The company first obtains a Licence to Operate for the manufacturing or importing entity after an on site inspection. Each product then needs its own Certificate of Product Registration, filed as an ASEAN Common Technical Dossier. Strategic investments can be designated for Green Lane processing under Executive Order 18, which prioritises the review but does not shorten the scientific assessment.

Do United States passport holders need a visa for a site visit?

No. A United States passport holder enters visa free for 30 days, extendable at the Bureau of Immigration. Register on the eTravel portal within 72 hours before arrival, hold a return or onward ticket, and carry a passport valid for at least six months beyond the stay.

Can RB Advertising supply the workwear for a Philippine operation?

Yes. RB Advertising produces laboratory coats, cleanroom compatible outerwear, scrubs, and corporate uniforms from Tagum City and Cagayan de Oro. Corporate programs start at twelve pieces per design, which suits a pilot site or a single office before a wider rollout, and we can quote against a plant floor plan rather than a catalogue.
Philippine Advisory Desk

Site Visit, Registration Route, or Uniform Rollout

Tell us which stage of the ladder you are on. We will map the visit, list the documents each agency will ask for, and quote the apparel the operation needs when it opens. This page is independent research, and the desk answers on that basis.

Mankilam Main Office, Tagum City

Naungayan Building, Aala Road, Barangay Mankilam, Tagum City, Davao del Norte 8100, Philippines. Production coordination and freight handover for Mindanao shipments.

Mon to Sat, 8:30 AM to 5:00 PM (PHT)

Cagayan de Oro Office

Ficcoville, Iponan, Cagayan de Oro City, Misamis Oriental, Philippines. Account support for buyers consolidating through the Northern Mindanao corridor.

Mon to Sat, 8:30 AM to 5:00 PM (PHT)

Sources

  1. ANI Pharmaceuticals, Inc., Annual Report on Form 10-K for the year ended 31 December 2025, filed 27 February 2026.
  2. ANI Pharmaceuticals, Inc., Quarterly Report on Form 10-Q for the quarter ended 30 September 2026, filed 5 November 2026.
  3. ANI Pharmaceuticals, Inc., Form 8-K and press release dated 5 November 2026, third quarter 2026 results and the recommended offer for Egetis Therapeutics AB.
  4. Republic Act 12066, Corporate Recovery and Tax Incentives for Enterprises to Maximize Opportunities for Reinvigorating the Economy Act, and its implementing rules.
  5. Republic Act 11647, amending the Foreign Investments Act of 1991, and Republic Act 7652, the Investors Lease Act.
  6. Republic Act 11981, the Tatak Pinoy Act, and the Food and Drug Administration of the Philippines licensing framework.
  7. Philippine Economic Zone Authority zone directory, the ASEAN Secretariat on the ASEAN Trade in Goods Agreement and the Regional Comprehensive Economic Partnership, and the Department of Tourism release of January 2026.

This is an independent research page published by RB Advertising of Tagum City and Cagayan de Oro. ANI Pharmaceuticals, Cortrophin, ILUVIEN, EMCITATE, Novitium, Alimera, and Egetis are the property of their respective owners. RB Advertising is not affiliated with any of them, has received no payment from any of them, and makes no representation about their plans in the Philippines. Nothing here is investment, legal, tax, or regulatory advice.